摘要: Rizatriptan benzoate is a 5 HT 1B/1D receptor agonist which is prescribed for the treatment of migraine. In the present study new, simple, specific ultraviolet spectrophotometric method for rizatriptan benzoate was developed and validated. Forced degradation studies were carried out in acidic, alkaline and neutral pH conditions. The absorbance maxima peak was found to be 224 nm and linearity was observed in the concentration range of 0.5~2.5 μg·mL-1 with regression coefficient value of 0.998 8. The method was validated and found to be precise. The percent recovery for rizatriptan benzoate was found to be 98.576±0.202. The bulk drug was found to be stable in neutral and acidic pH conditions but got degraded in 1 N NaOH solution.
Abstract:Rizatriptan benzoate is a 5 HT 1B/1D receptor agonist which is prescribed for the treatment of migraine. In the present study new, simple, specific ultraviolet spectrophotometric method for rizatriptan benzoate was developed and validated. Forced degradation studies were carried out in acidic, alkaline and neutral pH conditions. The absorbance maxima peak was found to be 224 nm and linearity was observed in the concentration range of 0.5~2.5 μg·mL-1 with regression coefficient value of 0.998 8. The method was validated and found to be precise. The percent recovery for rizatriptan benzoate was found to be 98.576±0.202. The bulk drug was found to be stable in neutral and acidic pH conditions but got degraded in 1 N NaOH solution.
Kempwade Amolkumar*, Taranalli Ashok, Jadhav Kiran . Development and Validation of UV Spectrophotometric Method to Study Stress Degradation Behaviour of Rizatriptan Benzoate [J]. 光谱学与光谱分析, 2015, 35(01): 137-140.
Kempwade Amolkumar*, Taranalli Ashok, Jadhav Kiran . Development and Validation of UV Spectrophotometric Method to Study Stress Degradation Behaviour of Rizatriptan Benzoate . SPECTROSCOPY AND SPECTRAL ANALYSIS, 2015, 35(01): 137-140.
[1] Chen J, Jiang X G, Jiang W M, et al. Pharmazie, 2005, 60(1): 39. [2] Amoozegar F, Pringsheim T. Patient Preference and Adherence, 2009,3: 251. [3] Jiang X, Chen J, Jiang W, et al. Journal of Chromatography B, 2004, 805: 169. [4] Shyamsundar B, Suneetha A. Ind. J. Pharm. Sci., 2010, 72(6): 798. [5] Basavaiah K, Prashanth K N. Journal of Saudi Chemical Society, Article in Press,2013. [6] Mallikarjuna B, Sangaraju S, Madhavan P,et al. J. Pharm. and Biomedical. Analysis, 2006, 41: 1146. [7] Jagtap S S, Gopu C L, Mahadik K R, et al. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 2010,1(2): 385. [8] International Conference on Harmonization. Stability Testing of New Drug Substances and Products Q1A (R2). IFPMA, Geneva,2003.